Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Intel is scheduled to report second-quarter results after the closing bell Thursday, with analysts tracked by Visible Alpha unanimously neutral amid questions surrounding the company's foundry ...

Wall Street's biggest bull sees tech and AI driving an 11% stock gain, fueled by strong fundamentals, M&A activity, and ...

In the recent 13F filings, Pfizer has seen a mix of investment adjustments from 11 institutions, reflecting a divided market ...

Oppenheimer initiated coverage of the buy now, pay later firm Monday, issuing an "outperform" rating for Affirm stock.

While its shares have been lagging the market significantly, that could change in the next decade as financial results ...

Pfizer recently recalibrated its evaluation score, a nod to shifting trends in the market and its own financial pulse. The ...

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over ...

The pharmaceutical sector continues to stand out as a resilient and highly profitable corner of the market, even amid global ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

Shares of Johnson & Johnson climbed 6.8% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for their biggest one-day gain and best postearnings reaction since ...